Methods for measuring proteasome activity: Current limitations and future developments

Andrea Liggett, Lisa Crawford, Brian Walker, Treen Morris, Alexandra Irvine

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


The proteasome has been validated as a therapeutic target, with proteasome inhibitors showing particular efficacy in the treatment of Multiple Myeloma. A wide range of methods have been developed to profile proteasome activity. These include the current method of choice fluorogenic peptide substrates, as well as bioluminescent imaging, immunological methods, and more recently, site-specific fluorescent probes. The aim of this review is to evaluate the currently available methods for profiling proteasome activity and their suitability for use in translational studies. Ongoing development of techniques for profiling proteasome activity will facilitate future research into proteasome-related pathologies, thus accelerating the development of more specific drug regimes. (C) 2010 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)1403-1409
Number of pages7
JournalLeukemia research
Issue number11
Publication statusPublished - Nov 2010

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Methods for measuring proteasome activity: Current limitations and future developments'. Together they form a unique fingerprint.

Cite this